PT Jayamas Medica Industri Tbk (OMED) Fair Value & Analysis
Healthcare · ID · Market cap 5.5T IDR
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 22 days ago
Fair value updated Jul 18, 2026, revised from 276.56 IDR to 276.39 IDR (−0.1%) since Jun 24, 2026. Share price +14.1% over the past month.
A solid business, screening 22% undervalued on our models.
What matters now
- Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from 187.72 IDR (bear) to 335.66 IDR (bull), base 276.39 IDR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 69/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
45‑month range 143.80 IDR – 303.86 IDR · fair‑value band 187.72 IDR – 335.66 IDR · the 226.00 IDR price screens below the 276.39 IDR fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
PT Jayamas Medica Industri Tbk (OMED) currently trades at 226.00 IDR, while our model-based Fair Value estimate is 276.39 IDR, implying the stock looks roughly 22.3% undervalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Jayamas Medica Industri Tbk generated revenue of 2.2T IDR at a net margin of 17.8%. Revenue grew 31.2% year over year. It earns a return on equity of 14.6%. The balance sheet holds a net cash position of 1.1T IDR. Fundamentals as of Jul 18, 2026
Our scenario range runs from 187.72 IDR (bear case) to 335.66 IDR (bull case); at 226.00 IDR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 36% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 22%, OMED screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (260.62 IDR) versus Dividend Discount (57.13 IDR). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Jayamas Medica Industri Tbk manufactures and sells medical devices in Indonesia, the United States of America, and South America. The company operates through three segments: Manufacturing, Distribution, and Retail.
Full company description
PT Jayamas Medica Industri Tbk manufactures and sells medical devices in Indonesia, the United States of America, and South America. The company operates through three segments: Manufacturing, Distribution, and Retail. It offers medical disposables and consumables comprising medical gloves, syringes, masks, gauze, bandages, urine bag, foley catheter, alcoholic tissue, etc.; antiseptic and disinfectant fluids, povidone iodine, medical alcohol, Hdsol or blood cleansing liquid, etc.; and diagnostics and equipment, such as patient monitor, vital signs monitor, ECG reader, syringe pump, infusion pump, blood pressure monitors, oximeter, fingertip pulse oximeters etc. The company also provides walking aids and rehabilitation care products, including wheelchairs, crutches, walkers, arm slings etc.; biotechnology and laboratory products, such as pregnancy test, PCR test, blood collection tube, PCT tube, chemical reagents, etc; and hospital furniture products comprising patient bed, bed side cabinet, children's patient bed, and operation lamp, as well as wound care products which include plasters, cotton, sterile gauze, etc. In addition, the company engages in warehousing and storage activities; and engages in the manufacturing, selling, and repairs and maintenance of medical devices. It retails medical supplies and equipment through Medicom stores and online platforms. PT Jayamas Medica Industri Tbk was founded in 2000 and is headquartered in Sidoarjo, Indonesia. PT Jayamas Medica Industri Tbk operates as a subsidiary of Pt. Intisumber Hasilsempurna.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Jayamas Medica Industri Tbk reported revenue of 2.1T IDR in FY2025 versus 2.2T IDR in FY2021, a compound −1.9%/yr. Reported net income was 367B IDR in FY2025, compounding −10.1%/yr from FY2021.
Watch OMED: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare PT Jayamas Medica Industri Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Jayamas Medica Industri Tbk (OMED) overvalued or undervalued?
What is the fair value of OMED?
What is the quality score of OMED?
What is the revenue of PT Jayamas Medica Industri Tbk (OMED)?
What is the net profit margin of OMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Jayamas Medica Industri Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.